findmyKOL
Clinical trialNCT06553872RecruitingPhase 2Interventional

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment60Mantle Cell Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Stanford Cancer Center

    Stanford, California, United States

    Saurabh Dahiya, MD
    Not, yet, recruiting
  • Univ of Miami - Sylvester Comprehensive Cancer Center

    Miami, Florida, United States

    Jay Spiegel, MD
    Recruiting
  • Moffitt Cancer Center

    Tampa, Florida, United States

    Aleksandr Lazaryan, MD, PhDBijal Shah, MDFarhad Khimani, MDFrederick Locke, MDJulio Chavez, MDMichael Jain, MD, PhDSameh Gaballa, MDSayeef Mirza, MDTaiga Nishihori, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Brexucabtagene autoleucel →Pirtobrutinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
23 Aug 2024
Primary completion
31 Aug 2029
Completion
31 Aug 2029
Last update posted
31 Mar 2026
Registered enrollment
60
Registry id
NCT06553872
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.